Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.

  • Revenue in USD (TTM)54.98bn
  • Net income in USD7.77bn
  • Incorporated1992
  • Employees94.30k
  • Location
    AstraZeneca PLC1 Francis Crick AvenueCambridge Biomedical CampusCAMBRIDGE CB2 0AAUnited KingdomGBR
  • Phone+44 207 304 5000
  • Fax+44 207 604 8151
  • Websitehttps://www.astrazeneca.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
AZN:LSE since
announced
Transaction
value
Esobiotec SrlDeal completed17 Mar 202517 Mar 2025Deal completed-15.62%1.00bn
Data delayed at least 20 minutes, as of Jun 30 2025 15:09 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.